WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), has announced a 10-year $1.4 billion (S$2 billion) investment plan to expand the company's research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore.

This new site will add 120,000L biomanufacturing capacity to WuXi Biologics' global network by 2026 and is anticipated to employ 1,500 research, development and manufacturing staff when complete.

Following the momentum of continued investments in the U.S., Ireland, Germany and China, this new addition in Singapore will become a critical part of the robust global supply chain network WuXi Biologics has established to fully meet the needs of global clients.

The centre will also reinforce WuXi Biologics' Global Dual Sourcing strategy, which ensures that customer projects can be fulfilled at multiple facilities globally to mitigate potential risks.

WuXi Biologics' investment plan is supported by the Singapore Economic Development Board (EDB).